KHDRBS1 and neoplasm: In contrast, KHDRBS1 KO HeLa tumours in the F1F3 group exhibited significantly reduced tumour weights compared to the PBS group (Fig. 5D), indicating increased sensitivity of KHDRBS1-deficient tumours to F1F3 treatment, which was consistent with our in vitro findings (Fig. 3C,F,L).